Canada: Competition Bureau Discontinues "Product Hopping" Investigation

The Competition Bureau, Canada's competition watchdog, announced in May 2014 that it was dropping its investigation into the life cycle management strategy used by Alcon Canada Inc. in connection with its Patanol and Pataday products.  The Bureau commenced an inquiry in November 2012 to examine whether Alcon was dominant in a relevant market and if so, "whether it had intentionally disrupted the supply of its prescription ocular anti-allergy drug, Patanol, as part of a strategy to switch patients to a second generation formula of the drug and hinder meaningful competition from generic drug companies."1  After a thorough review, the Bureau ended its investigation upon concluding that the competitive dynamic had returned in the market and that Alcon's strategy did not appear to have delayed generic entry.

By law, the Bureau is required to conduct its inquiries in private.2 However, this matter came to light when the Bureau sought a court order under section 11 of the Competition Act compelling Alcon to produce records and written responses to its questions in December 2012.  As well, upon the conclusion of its inquiry, the Bureau issued a press release and position statement explaining the nature of its inquiry and the reasons for discontinuing its investigation.  Product hopping has been investigated by a number of competition agencies around the world, and the Bureau's position statement provides helpful guidance for pharmaceutical firms in Canada contemplating such conduct.

Conduct at issue

The Bureau learned that, beginning around July 2012, Alcon adopted a strategy that involved suspending the supply of Patanol from the Canadian market, which they allege was designed to switch prescriptions for Patanol to a new Alcon product, Pataday, a second generation reformulation of the drug found in Patanol.  The medicinal ingredient in Patanol was protected by patent until November 2012, whereas the medicinal ingredient in Pataday was patent protected until 2022.  

Apotex Inc. sought to introduce a generic version of Patanol, and served a Notice of Application on Alcon in February 2010.  Alcon contested the application, and Alcon's application contesting Apotex's allegations was heard by the Federal Court in early 2012.  In April 2012, based on a settlement Alcon believed it had reached with Apotex, Alcon discontinued the Federal Court litigation.  Health Canada issued a Notice of Compliance to Apotex for its generic version of Patanol on November 22, 2012, the day after the patent on the medicinal ingredient expired.

With the limited availability of Patanol in the Canadian market in the summer of 2012, doctors moved many Patanol patients to Pataday.  The Bureau was concerned that generic competition could be delayed or prevented as a result of Alcon's conduct because the automatic substitution rules for generic drugs can only be relied upon where the original brand name drug is being prescribed.  Pharmacists could not automatically substitute generic Patanol if Patanol was not being prescribed by doctors.

Result of the Bureau's inquiry

Alcon resumed supplying Patanol to the Canadian market in January 2013 after the Bureau's inquiry was started.  By May 2013, it was observed that sales of Patanol were back where they had been before the supply disruption.  As well, generic versions of Patanol entered the market and did gain significant market share.  For these reasons, the Commissioner ended his inquiry as "the competitive dynamic appears to have been restored."  

Implications the inquiry

The Bureau's statement makes clear that the Bureau does not consider life-cycle management strategies to be "inherently anti-competitive."  They note that these strategies may bring "significant advancements in health care for the benefit of consumers."  However, they emphasize that life-cycle management strategies that are "designed to impede competition from generic drug companies, such as product switching strategies, may cause significant harm to competition."  The following conduct is flagged as raising likely concerns under the abuse of dominance provisions: disrupting supply to forcibly switch demand, including terminating, repurchasing, or recalling market supply; or other attempts to frustrate supply of a product under patent challenge by a potential generic competitor.  It thus appears that the Bureau's investigation in Alcon focused on whether limiting supply to move prescriptions from Patanol to Pataday prior to the entry of a generic version of Patanol resulted in anti-competitive effects.

However, the Bureau's statement does not discuss in what circumstances the removal of an old product and its replacement by a new version (for which a separate patent was obtained) can amount to an "anti-competitive act" under the abuse of dominance provisions.  Is the simple discontinuation of supply of a product to replace it by a new, improved one with increased therapeutic benefits enough?  When does a limitation of supply amount to an intended predatory, exclusionary or disciplinary negative effect on a competitor?  There are issues that remain to be determined. Although the Competition Bureau is not the final arbiter of misconduct under the Act – the Commissioner must prove his case before the Competition Tribunal – firms are well advised to heed the views expressed in the position statement as a reflection of the enforcement policies and priorities of the Commissioner and its increased interest in the pharmaceutical industry.  The Tribunal is authorized to impose administrative monetary penalties on a corporation of up to $10 million for the violation of the abuse of dominance provisions, with subsequent violations subject to a  maximum penalty of $15 million.

Link to Competition Bureau announcement

Competition Bureau discontinues its investigation of Alcon Canada Inc.


1 Competition Bureau Statement Regarding the Inquiry into Alleged Anti-Competitive Conduct by Alcon Canada Inc., May 13, 2014.

2 Competition Act, R.S.C. 1985, c. C-34, s. 10.

Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Gowling WLG
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Gowling WLG
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions